MBT/Pas mouse: a relevant model for the evaluation of Rift Valley fever vaccines.

Abstract

Currently, there are no worldwide licensed vaccines for Rift Valley fever (RVF) that are both safe and effective. Development and evaluation of vaccines, diagnostics and treatments depend on the availability of appropriate animal models. Animal models are also necessary to understand the basic pathobiology of infection. Here, we report the use of an inbred MBT/Pas mouse model that consistently reproduces RVF disease and serves our purpose for testing the efficacy of vaccine candidates; an attenuated Rift Valley fever virus (RVFV) and a recombinant RVFV-capripoxvirus. We show that this model is relevant for vaccine testing.

• Authors: Emna Ayari-Fakhfakh, Tânia Zaverucha do Valle, Laurent Guillemot, Jean-Jacques Panthier, Michèle Bouloy, Abdeljelil Ghram, Emmanuel Albina, Catherine Cêtre-Sossah
• Journal: The Journal of general virology (J Gen Virol) Vol. 93 Issue Pt 7 Pg. 1456-1464 (Jul 2012) ISSN: 1465-2099 [Electronic] England
• PMID: 22513390 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Vaccines, Attenuated
• Viral Vaccines

Topics

• Animals
• Disease Models, Animal
• Drug Evaluation, Preclinical (methods)
• Female
• Humans
• Mice
• Rift Valley Fever (immunology, prevention & control)
• Rift Valley fever virus (immunology)
• Vaccination (methods)
• Vaccines, Attenuated (administration & dosage, immunology)
• Viral Vaccines (administration & dosage, immunology)